TCE

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Well, Small-cell carcinoma, Therapeutic index, Glomus tumor, Endometrial cancer, Survival, Environment, Service provider, Trichloroethylene, Patient, Primate, Triple-negative breast cancer, Lead, Zymeworks, 3D, Standard of care, Cancer, TAA, Spacecraft, Lung cancer, IND, CD3, DLL3, AACR, Workflow, Antibody, TCE, CD28, Therapy, Stomach, ADC, Vaccine

The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.

Key Points: 
  • The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
  • An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
  • Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024

Retrieved on: 
Friday, April 5, 2024
Cell, Trichloroethylene, Patient, Lung, Epitope, Breast, KK, Allele, AACR, Cancer, Antibody, TCE, Therapy, Peptide, Vaccine

Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.

Key Points: 
  • Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.
  • However, high levels of similar off-target peptides presented in healthy tissues make targeting the KK-LC-1/HLA-A*01 challenging.
  • CDR-Life’s data gathered on pMHC TCE antibodies with high specificity towards HLA-A*01 restricted KK-LC-1 epitopes demonstrate the antibodies’ promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors.
  • In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides.

TEN Ltd. Reports Record Profits for Year-End and Fourth Quarter 2023 Results and Dividend of $0.60 per Common Share

Retrieved on: 
Wednesday, March 27, 2024
Employment, Growth, Environment, Depreciation, TNP, Interest, TCE, LNG, LR2, Cryptocurrency

Greece, March 27, 2024 (GLOBE NEWSWIRE) -- TEN, Ltd. (TEN) (NYSE: TNP) (the “Company”) reports results (unaudited) for the fourth quarter and the year ended December 31, 2023.

Key Points: 
  • Greece, March 27, 2024 (GLOBE NEWSWIRE) -- TEN, Ltd. (TEN) (NYSE: TNP) (the “Company”) reports results (unaudited) for the fourth quarter and the year ended December 31, 2023.
  • The Company’s total debt obligations were reduced from the 2022 level and settled at $1.56 billion at December 31, 2023.
  • This elevated rate environment resulted to an increase of interest income from $2 million in 2022 to $15 million in 2023.
  • Fleet utilization reached 98.3% in the fourth quarter of 2023 from a still high 97.4% in the 2022 fourth quarter due to the increase of vessels in time-charter employment.

C3is Inc. reports Revenue of $13.8 million, Net Income of $5.6 million and $0.25 earnings per diluted share for the fourth quarter of 2023, and financial and operating results for the quarter and twelve months ended December 31, 2023

Retrieved on: 
Tuesday, March 26, 2024
Administration, Environment, EPS, Webcast, CISS, Imperial, Acquisition, Transport, Depreciation, Interest, TCE, Asset, Calendar, Airline

Voyage revenues of $28.7 million for the twelve months ended December 31, 2023, corresponding to a daily TCE1 of $23,453.

Key Points: 
  • Voyage revenues of $28.7 million for the twelve months ended December 31, 2023, corresponding to a daily TCE1 of $23,453.
  • Our Company generated a net income of $9.3 million for the twelve months ended December 31, 2023, and a net income of $5.6 million for the three months ended December 31, 2023.
  • 69.7% increase in Net Income to $5.6 million for the three months ended December 31, 2023, from $3.3 million for the three months ended September 30, 2023.
  • 45.3% increase in EBITDA2 to $7.7 million for the three months ended December 31, 2023, from $5.3 million for the three months ended September 30, 2023.

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, 5T4, Translational research, Autoimmunity, Risk, Trichloroethylene, SVP, Cancer, Protein, CD3, Translation, AACR, Doctor of Philosophy, MHC, ABCL, TCE, Safety, CD28, San Diego Convention Center, PSMA, Peptide, Pharmaceutical industry

Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.

Key Points: 
  • Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.
  • “Our data illustrate that we can repeatedly generate TCEs that maximize tumor-cell killing without inducing excessive cytokine release.
  • The data show that AbCellera’s IgG and heavy chain-only CD28-binding antibodies do not display superagonist activity — a property associated with toxicity.
  • “We look forward to advancing these programs with the aim of delivering powerful new medicines for patients.”

Antengene Presents Four Preclinical Posters at AACR 2024

Retrieved on: 
Saturday, April 6, 2024
PRMT5, AML, CDX, Risk, Weight loss, LILRB4, MTAP, Acute myeloid leukemia, CRS, Cancer, IND, AACR, PDX, Antibody, DDI, TCE, Immunohistochemistry, San Diego Convention Center, Cytokine release syndrome, Vaccine

SHANGHAI and HONG KONG, April 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.

Key Points: 
  • SHANGHAI and HONG KONG, April 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four preclinical posters at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024), taking place from April 5th to April 10th at the San Diego Convention Center in San Diego, California, the United States.
  • Study results showed that ATG-042 has the potential to elegantly target tumor cells while sparing healthy cells, with an attractive developability profile.
  • 12:00 AM - 3:30 AM, April 10, 2024 (Beijing Time)
    This preclinical study was designed to test the in vitro/in vivo efficacy, and preclinical pharmacokinetic (PK) properties of ATG-042.
  • This poster presents the discovery and validation of a novel, highly sensitive immunohistochemistry (IHC) antibody that selectively identifies CLDN18.2.

VANTAGE TO HIGHLIGHT NEW iSAP™ 311 INHIBITED SURFACE ADHESION PROMOTER AT MRO AMERICAS

Retrieved on: 
Thursday, March 21, 2024
Aircraft, Tetrachloroethylene, Professional baseball, Vantage, Elastomer, Trichloroethylene, MRO, Corrosion, Plastic, TCE, PERC, FS, Dry cleaning

Deerfield, Ill., March 21, 2024 (GLOBE NEWSWIRE) -- Vantage, a global supplier of surface treatment technologies, will highlight its new iSAP 311 Inhibited Surface Adhesion Promoter as part of a complete range of cleaning solutions and surface preparation products for commercial, military and general aviation at MRO Americas (Booth 652) in Chicago, Illinois April 9 – 11, 2024.

Key Points: 
  • Deerfield, Ill., March 21, 2024 (GLOBE NEWSWIRE) -- Vantage, a global supplier of surface treatment technologies, will highlight its new iSAP 311 Inhibited Surface Adhesion Promoter as part of a complete range of cleaning solutions and surface preparation products for commercial, military and general aviation at MRO Americas (Booth 652) in Chicago, Illinois April 9 – 11, 2024.
  • Launched in 2023, its iSAP 311 Inhibited Surface Adhesion Promoter is an advanced non-chromated surface pretreatment, engineered to provide both adhesion promotion and corrosion resistance before the application of multi-layered paint system stack-ups.
  • “Our commitment to expanding our market expertise reinforces our position as technical leaders in surface treatment technologies.
  • iTPC™ 37 Remover Inhibited Temporary Protective Coating Remover – A ready to use inhibited, water-based cleaning solution formulated to remove strippable temporary protective coatings (TPCs).

Overseas Shipholding Group Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, March 11, 2024
Maritime, Transport, Oil, Gas, Manufacturing, Energy, Other Manufacturing, OSG, Overseas Shipholding Group, Employment, Exploration, Webcast, American Shipping Company, Investment, TCE, Page Eight, Video game

Fourth quarter 2023 Adjusted EBITDA was $47.3 million, an increase of $3.6 million, or 8.4%, from the fourth quarter of 2022.

Key Points: 
  • Fourth quarter 2023 Adjusted EBITDA was $47.3 million, an increase of $3.6 million, or 8.4%, from the fourth quarter of 2022.
  • Shipping revenues for the fourth quarter of 2023 were $116.0 million, a decrease of $5.7 million, or 4.7%, compared to the fourth quarter of 2022.
  • TCE revenues for the fourth quarter of 2023 were $110.1 million, a decrease of $4.0 million, or 3.5%, compared to the fourth quarter of 2022.
  • Operating income for the fourth quarter of 2023 was $25.9 million compared to operating income of $20.4 million for the fourth quarter of 2022.

BRENDA SOLÓRZANO NAMED PRESIDENT/CEO OF THE CALIFORNIA ENDOWMENT

Retrieved on: 
Friday, March 22, 2024
Endowment, Health equity, Partnership, History, University, Whittier Law School, TCE, River source, Blood

Solórzano is a familiar face to The California Endowment, having begun her career in health philanthropy at the foundation in 2001.

Key Points: 
  • Solórzano is a familiar face to The California Endowment, having begun her career in health philanthropy at the foundation in 2001.
  • "The California Endowment is where I learned the value of centering community in philanthropic work, and it is something I have carried throughout my career," said Solórzano.
  • "Brenda Solórzano exemplifies what TCE stands for and is working to build an inclusive California where everyone belongs.
  • Benda Solórzano will take over the reins at The California Endowment in early September 2024.

Goldhirsh Foundation Names Groundbreaking All-Female Investment Committee

Retrieved on: 
Thursday, March 14, 2024
Cream, Boston University, AB, City, NationBuilder, TCE, UCLA, CIO, HEC Paris, Bookshop (company), Harvard University, BBDO, Wilshire Associates, Brown University, Woman, CFA, Committee on Finance, SpaceX, Larchmont Charter School, Saatchi & Saatchi, Organization, Eric Schmidt, Chopped, Planet Labs, Acquisition, University, Food, ASTR, American Dream, M13, LOS, The arts, School, Samuel Adams, MBA, Coolhaus, YPO, Zagat, CIV, Shana, Partner, Collaborative Fund

LOS ANGELES, March 14, 2024 /PRNewswire/ -- Today, the Goldhirsh Foundation announced its new all-female investment committee—believed to be the first such investment committee at an organization of its size and scope. The committee members are: Shana Barghouti, Natasha Case, Celestine Schnugg, and Ruth Wernig.

Key Points: 
  • This new, all-female, investment committee is believed to be the first such at an organization of this size and scope.
  • "All four women on our new investment committee have proven themselves as business and civic leaders, as well as visionaries, during the course of their careers," said Tara Roth, President of the Goldhirsh Foundation.
  • The new committee – with the experience, network, and expertise they bring – further solidifies a strategic shift for the Goldhirsh Foundation's endowment.
  • Meet the members of the Goldhirsh Foundation investment committee:
    Shana Barghouti, Co-Chief Investment Officer at ReMY Investors, a multi-family investment firm based in Los Angeles.